Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

553 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Rai S, et al. Among authors: kuroda j. Haematologica. 2023 Mar 1;108(3):811-821. doi: 10.3324/haematol.2022.280996. Haematologica. 2023. PMID: 36200417 Free PMC article.
Cyclosporine A for chemotherapy-resistant subcutaneous panniculitis-like T cell lymphoma with hemophagocytic syndrome.
Mizutani S, Kuroda J, Shimura Y, Kobayashi T, Tsutsumi Y, Yamashita M, Yamamoto M, Ohshiro M, Sasaki N, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Nakamura S, Taniwaki M. Mizutani S, et al. Among authors: kuroda j. Acta Haematol. 2011;126(1):8-12. doi: 10.1159/000323565. Epub 2011 Mar 17. Acta Haematol. 2011. PMID: 21411984
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Kobayashi T, Kuroda J, Fuchida S, Kaneko H, Yagi H, Shibayama H, Tanaka H, Kosugi S, Uoshima N, Kobayashi M, Adachi Y, Ohta K, Ishii K, Uchiyama H, Matsuda M, Nakatani E, Tsudo M, Shimazaki C, Takaori-Kondo A, Nomura S, Matsumura I, Taniwaki M, Kanakura Y; KMF investigators. Kobayashi T, et al. Among authors: kuroda j. Int J Hematol. 2015 Jan;101(1):37-45. doi: 10.1007/s12185-014-1696-6. Epub 2014 Nov 11. Int J Hematol. 2015. PMID: 25385278
[Long-term follow-up results of a phase I/II study of melphalan, prednisolone and bortezomib in Japanese transplant-ineligible multiple myeloma patients (JPN-102)].
Ogiya D, Shibayama H, Nakatani E, Ando K, Suzuki K, Kuroda Y, Uchida T, Maruyama D, Matsumoto M, Matsue K, Iida S, Terui Y, Ri M, Chou T, Aotsuka N, Tabata S, Konishi J, Ohashi K, Shinagawa A, Sugiura I, Kuroda J, Miyamoto T, Ogura M, Tobinai K, Kanakura Y, Hotta T. Ogiya D, et al. Among authors: kuroda j, kuroda y. Rinsho Ketsueki. 2016;57(11):2311-2318. doi: 10.11406/rinketsu.57.2311. Rinsho Ketsueki. 2016. PMID: 27941278 Clinical Trial. Japanese.
Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial).
Ishikawa J, Matsumura I, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Matsuoka KI, Shibayama H, Hino M, Hirase C, Kamimura T, Shimose T, Akashi K, Kanakura Y. Ishikawa J, et al. Among authors: kuroda j. Int J Hematol. 2018 May;107(5):535-540. doi: 10.1007/s12185-018-2401-y. Epub 2018 Jan 23. Int J Hematol. 2018. PMID: 29362980 Clinical Trial.
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; Kansai Myeloma Forum Investigators. Matsumura-Kimoto Y, et al. Among authors: kuroda j. Int J Hematol. 2018 May;107(5):541-550. doi: 10.1007/s12185-018-2416-4. Epub 2018 Jan 29. Int J Hematol. 2018. PMID: 29380179
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Iida S, Wakabayashi M, Tsukasaki K, Miyamoto K, Maruyama D, Yamamoto K, Takatsuka Y, Kusumoto S, Kuroda J, Ando K, Kikukawa Y, Masaki Y, Kobayashi M, Hanamura I, Asai H, Nagai H, Shimada K, Tsukamoto N, Inoue Y, Tobinai K. Iida S, et al. Among authors: kuroda j. Cancer Sci. 2018 May;109(5):1552-1561. doi: 10.1111/cas.13550. Epub 2018 Apr 17. Cancer Sci. 2018. PMID: 29478257 Free PMC article. Clinical Trial.
553 results